Presentations at European Stroke Organisation Conference
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Argenica Therapeutics Ltd announced the acceptance of two abstracts for presentation at the European Stroke Organisation Conference, highlighting their Phase II stroke trial results. The poster presentation has been recognized as a Best Poster Finalist, indicating its high quality and impact among submissions. Dr Liz Dallimore emphasized the significance of being selected for both an oral and poster presentation at this prestigious conference.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Argenica Receives $3.97m R&D Tax Incentive Cash Rebate
- Half Yearly Report and Accounts
- Successful Applicaton for EMA Paediatric Waiver
- Quarterly Activities/Appendix 4C Cash Flow Report
- AI Analysis Reveals Efficacy In Severe Stroke Patients
Later from Argenica Therapeutics
- Clinical Advisory Committee Established to Advance Phase 2b
- IND Application Advanced With Successful Completion of Assay
- WHO Confirms Xaranetide as INN for ARG-007
- ARG007 (Xaranetide) Completes All Three FDA Requested Assays
- ARG007 Shows Significant Neuroprotection in Concussion Study
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics